Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.86 |
| ▸ | CDC25B | P30305 | 2/20 | 0.86 |
| ▸ | MAOA | P21397 | 4/20 | 0.80 |
| ▸ | S100A4 | P26447 | 3/20 | 0.80 |
| ▸ | TDP2 | O95551 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | APAF1 | O14727 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.80 |
| ▸ | PTPRC | P08575 | 2/20 | 0.80 |
| ▸ | CES2 | O00748 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31884 | 0.96 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL29378679 | 0.96 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL30479684 | 0.96 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL20203661 | 0.96 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOAS100A4 | |
| 9,10-Phenanthrenequinone SCHEMBL11634370 | 0.93 | S100A4 (0.93) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL29039854 | 0.93 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOAS100A4 | |
| 9,10-Phenanthrenequinone SCHEMBL29746976 | 0.93 | S100A4 (0.93) | MEN1KMT2ACDC25BMAOAS100A4 | |
| Water SCHEMBL7789828 | 0.93 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL29009485 | 0.93 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOAS100A4 | |
| SCHEMBL29615309 | 0.93 | MEN1 (0.86) | MEN1KMT2ACDC25BMAOAS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | MEN1 3097/4885KMT2A 4847/4885CDC25B 1347/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | MEN1 3097/4885KMT2A 4847/4885CDC25B 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.